Related Experiment Video

Updated: Jun 12, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

PI3K pathway-directed therapeutic strategies in cancer

Roshan Agarwal1, Mark Carey, Bryan Hennessy

  • 1Imperial College London, Department of Oncology, Hammersmith Hospital, Du Cane Road, W12 0NN, UK. Roshan.Agarwal@imperial.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|May 25, 2010
PubMed

Insights

The phosphoinositide 3-kinase (PI3K) pathway is a promising target for cancer drug development. This review covers PI3K pathway drugs in clinical trials and their therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphoinositide 3-kinase (PI3K) pathway is frequently dysregulated in various cancers.
  • Targeting the PI3K pathway is a key strategy in current oncology drug development.
  • Numerous academic institutions and pharmaceutical companies are actively researching this pathway.

Purpose of the Study:

  • To review the evidence supporting the PI3K pathway as a viable cancer drug target.
  • To discuss various therapeutic strategies for targeting the PI3K pathway in cancer.
  • To provide an overview of PI3K-targeting drugs currently in clinical development.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of therapeutic strategies targeting different components of the PI3K pathway.
  • Compilation of data on PI3K-targeting drugs in clinical trials.

Main Results:

  • Evidence supports the PI3K pathway as a suitable target for anti-cancer drug development.
  • Multiple therapeutic strategies are being explored to inhibit or modulate the PI3K pathway.
  • Several PI3K-targeting drugs are in various phases of early clinical trials.

Conclusions:

  • The PI3K pathway holds significant promise as a target for novel cancer therapies.
  • Ongoing clinical trials will determine the efficacy and safety of PI3K-targeting drugs.
  • Further research is warranted to optimize therapeutic strategies and drug combinations.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...